Summit Therapeutics (SMMT) Short term Debt (2019)
Summit Therapeutics (SMMT) posted quarterly Short term Debt of $105000.0 for Q4 2019.
Summit Therapeutics (SMMT) Short term Debt (2019) Analysis & Trends
Summit Therapeutics (SMMT) has reported Short term Debt for 1 consecutive years, with $105000.0 the latest figure, recorded in Q4 2019.
- Quarterly Short term Debt changed N/A year-over-year to $105000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $105000.0 (changed N/A YoY) and the FY2019 annual result came in at $105000.0, changed N/A from the prior year.
- Short term Debt steadied at $105000.0 in Q4 2019 per SMMT's latest filing.
- Over the last five years, Short term Debt for SMMT reached as high as $105000.0 in Q4 2019 and fell as low as $105000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Summit Therapeutics | 11.62 Bn | 11.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 105,000.00 |